Kiromic BioPharma gives follow-up results for 1st patient in Deltacel trial

Kiromic BioPharma reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel or KB-GDT-01, the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell GDT therapy, in patients with stage 4 metastatic non-small cell lung cancer NSCLC who have failed to respond to standard therapies. “As this patient is the most advanced in our ongoing Deltacel-01 clinical trial, we are particularly encouraged by these latest follow-up results that continue to validate the potential of Deltacel as a safe and effective treatment for patients with later-stage cancers,” said Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “We believe these findings underscore the promise of our allogeneic GDT therapy in providing durable clinical benefit.” …Continued meaningful results could represent a significant breakthrough for these late-stage cancer patients with limited treatment options.”…Kiromic expects to report additional follow-up results from the fourth patient enrolled in this study in October.